IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Theravance Biopharma Inc (TBPH)

CUSIP: G8807B106 | 551 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/AWeiss Asset Management LP00.0%Fell below 5%Sep 23, 202685d ahead of 13F (7,457,060 sh) · −7,457,060
13G/AMadison Avenue GP, LLC9,212,25217.7%New 5%+ stakeJun 30, 2026No 13F filer matched
13G/ANewtyn Management, LLC
with Newtyn TE Partners, LP
3,434,1916.7%New 5%+ stakeJun 30, 2026No 13F filer matched
13D/AWeiss Asset Management LP0
0.0% of class · Sep 23, 2026Fell below 5%
85d ahead of 13F (7,457,060 sh) · −7,457,060
13G/AMadison Avenue GP, LLC9,212,252
17.7% of class · Jun 30, 2026New 5%+ stake
No 13F filer matched
13G/ANewtyn Management, LLC3,434,191
6.7% of class · Jun 30, 2026New 5%+ stake
with Newtyn TE Partners, LP
No 13F filer matched

Institutional Holders — Q3 2026

IFP Advisors, Inc3
0.0% of portfolio›$51
StyleTurnoverLocationFiled
IFP Advisors, Inc
3$510.0%GrowthLowTampa, FL2026-10-16